EcoDrugPlus

Melanocortin 4 Receptor

Ensembl ID : ENSSTUG00000011960
Gene Symbol: MC4R
1 Cross references
24 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSSTUG00000009292
Gene Symbol: MC4R
1 Cross references
76 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSSTUG00000011392
Gene Symbol: MC4R
3 Cross references
76 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSSTUG00000045092
Gene Symbol: MC4R
1 Cross references
24 Possible Orthologues:

Melanocortin Receptor 3-Like

Ensembl ID : ENSSTUG00000009650
Gene Symbol: LOC115168864
3 Cross references
133 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSSTUG00000017970
Gene Symbol: LOC115195550
2 Cross references
208 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSSTUG00000038291
Gene Symbol: MTNR1A
3 Cross references
136 Possible Orthologues:

Melatonin Receptor Type 1a-A

Ensembl ID : ENSSTUG00000046260
Gene Symbol: LOC115191904
3 Cross references
179 Possible Orthologues:

Melatonin Receptor Type 1a-A-Like

Ensembl ID : ENSSTUG00000034317
Gene Symbol: LOC115202133
3 Cross references
180 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSSTUG00000033546
Gene Symbol: MME
3 Cross references
227 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSSTUG00000007264
Gene Symbol: MME
3 Cross references
228 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSSTUG00000028947
Gene Symbol: LOC115208110
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).